President Trump's Proposed Tariffs on Generic Drug Imports Threaten U.S. Healthcare Costs and Supply Chains
President Trump has indicated a potential policy shift that could impose significant tariffs on generic drugs imported into the U.S. While generic medicines were previously exempt from tariffs on imported pharmaceuticals, a July post by President Trump suggested that generic imports could face a 100% tariff in the first year of the policy, escalating to 200% in the subsequent year. This proposal is part of a broader policy push to encourage domestic manufacturing, particularly for Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The FDA is aligning with this initiative, with new Generic Drug User Fee Amendments (GDUFA) for 2028-2032 including a $10,000 increase in the foreign facility differential, raising it from $15,000 to $25,000 to cover increased inspection costs for foreign facilities. Additionally, the FDA has proposed a one-time waiver for domestically produced drugs if the API is also produced in the U.S., and amendments to Priority ANDA review to prioritize U.S.-produced drug p... 
